WuXi XDC Cayman Inc. (the “Company”) released an announcement confirming the completion of its connected transaction involving the subscription of new shares under a specific mandate. According to the disclosure, an aggregate of 24,134,000 new shares were subscribed on October 22, 2025, by WuXi Biologics at a subscription price of HK$58.85 per share.

The net proceeds from this transaction, following the deduction of relevant fees and expenses, stand at approximately HK$1,414.47 million (equivalent to around US$181.25 million), translating to a net subscription price of about HK$58.61 per share.

Upon completion, the Company’s shareholding structure has changed. WuXi Biologics now holds roughly 50.72% of the issued share capital, up from 49.75%. STA Pharmaceutical Hong Kong Investment Limited maintains an approximate 18.59% stake, Dr. Zhisheng Chen continues to hold about 0.03%, and other public shareholders hold around 30.65%. The total number of issued shares of the Company has increased from 1,228,727,617 to 1,252,861,617.

The announcement reiterates that the newly issued shares have not been registered under the US Securities Act of 1933, and they are not offered or sold in the United States unless pursuant to an applicable exemption. As of October 22, 2025, the board of directors consists of executive, non-executive, and independent non-executive directors, and no changes to board composition were disclosed in the announcement.